KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Assets Average (2019 - 2025)

Castle Biosciences (CSTL) has disclosed Assets Average for 7 consecutive years, with $570.7 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 9.14% to $570.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $570.7 million through Dec 2025, up 9.14% year-over-year, with the annual reading at $554.9 million for FY2025, 12.72% up from the prior year.
  • Assets Average hit $570.7 million in Q4 2025 for Castle Biosciences, up from $553.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $570.7 million in Q4 2025 to a low of $426.1 million in Q2 2023.
  • Historically, Assets Average has averaged $471.4 million across 5 years, with a median of $453.0 million in 2022.
  • Biggest five-year swings in Assets Average: soared 265.27% in 2021 and later dropped 5.98% in 2023.
  • Year by year, Assets Average stood at $448.1 million in 2021, then rose by 0.99% to $452.6 million in 2022, then decreased by 1.74% to $444.7 million in 2023, then grew by 17.59% to $522.9 million in 2024, then rose by 9.14% to $570.7 million in 2025.
  • Business Quant data shows Assets Average for CSTL at $570.7 million in Q4 2025, $553.8 million in Q3 2025, and $523.2 million in Q2 2025.